A team of investigators have uncovered a rare genetic mutation that enables some blood cancers to evade both approved Bruton tyrosine kinase inhibitors and newer BTK degraders.
Researchers at Moffitt Cancer Center have developed a chemical approach that could help make targeted cancer medicines safer and more precise.
